Tough competition prior to relocation of EMA after Brexit
“EMA would be a boost to Swedish biotech and drug development,” says Thomas Lönngren*, former Executive Director, EMA 2001-2010, in an interview about the Swedish candidacy for the European Medicines Agency. And that’s an opinion that the Swedish government shares, being one of the first EU members to announce its interest for hosting EMA after Brexit in 2019.
The European Medicines Agency (EMA) is responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU and crucial for the functioning of its single market for medicines. The agency is one of two that will be relocated in the context of the UK’s withdrawal from the EU.
As well as increased opportunities to attract investment from international pharmaceutical companies, EMA will bring considerable economic benefits to its new host country. The agency employs more than 900 people, paid by the EU, and around 40,000 experts attend meetings within the framework of EMA activities every year.
It’s not surprising, therefore, that a vast majority of EU member countries has expressed an interest in hosting the agency. After the deadline for application, 19 candidates will compete for the relocation. All are confident that their offer will be the best for the authority and provide a seamless transition. See them all here.
Among the arguments stressed in the Swedish application to convince other member states that Sweden and Stockholm is best suited to host the EMA, is the Swedish Medical Products Agency (MPA) in Uppsala. MPA is already one of the most active partners of the EMA, second only to the UK when it comes to contributions. The MPA is prepared to shoulder up to ten percent of the UK’s workload once the country exits the EU. Another argument is the European Centre for Disease Prevention and Control (ECDC), already established in Stockholm. Close geographical proximity of the ECDC and EMA may contribute to synergy effects and facilitate the agencies’ collaboration for serious healthcare threats like anti-microbial resistance. Otherwise, as in all the other proposals, we must describe how we can fulfil the six criteria stipulated and decided by 27 EU leaders: the agency is operational when the UK leaves the EU; accessibility of the location; schools for the children of the agency staff; access to the labour market and healthcare for employees’ spouses and children; business continuity; geographical spread. Concerning the last two criteria, Sweden stresses that when it comes to an already existing agency, business continuity must be prioritised over geographical aspects.
See the “EMAtoSweden Pitchfilm”
So what happens now? An assessment of the offers by the Commission based on the agreed criteria should be presented in September 2017 and the General Affairs Council will decide on the relocation of EMA in November 2017. Meanwhile, the Swedish EMA-secretariat and actors in the Stockholm – Uppsala life science cluster will continue to convince other EU countries that our application is the best. If you want to contribute – use #ematosweden
Director of Communication
Uppsala BIO helps Testa Center off to a flying start
Process based on successful BIO-X methodology.>>
“You can make a holding company profitable, but it takes a bit of luck.”
This autumn, Lars Jonsson, CEO of UU Holding since 1998, retires and hands over a very successful investment business to his successor. “UU Holding is nothing short of a success story,” writes Uppsala BIO’s Erik Forsberg. Lars Jonsson has proven that it is possible to make a holding company profitable.>>
Uppsala’s innovation support system works! Award-winning Kontigo Care is the latest proof.
“With its high costs and huge suffering for those affected as well as their relatives, alcohol abuse is one of our major social problems. Kontigo Care’s work on digital biomarkers is one of the most exciting things I’ve witnessed during my career,” writes Uppsala BIO Buiness Developer Magnus Engevik.>>
Spotlight Uppsala’s unique resource!
Uppsala’s life science industry is healthy and developing well. More than 100 life science companies can be found here and in 2016 they employed about 5000 people and had a combined turnover of approximately SEK 27 billion.>>
“What happens in Vegas stays in Vegas…”
During 52 hours, staff from the Academic Hospital, AbbVie, Bristol Myers-Squibb and Microsoft worked together to develop and test new ideas and models for early diagnosis and better treatment of cancer. Now the experiences of Sweden's first “Innovation Race” can be summed up.>>
50 years of excellence – it all started with a collaboration between academia and industry!
2017 marks the 50 year anniversary of the RAST-method. Learn about the history and see how Uppsala BIO and UU Innovation are addressing future challenges in asthma and allergy diagnostics.>>
Sweden needs new regulations and ways for collaboration to stay ahead in healthcare and the life sciences
Challenges and opportunities for countries wanting to take a leading role in life sciences, with focus on the future role of Sweden, was the topic of a seminar in May 2017. In our blog Johan Gómez de la Torre, Business Development Manager, Stockholm Science City digest the report.>>
Call for proposals: A pull to transform inventions into innovations
How do we pull out the good ideas that may become new innovative products or treatments for the benefit of patients? Calls for project proposals may be the pull that is needed.>>
Uppsala Health Summit 2017: Time for the world to meet on Infectious Disease Threats
10 – 11 October Uppsala Health Summit gathered 200 decision makers and experts from 30 different countries in a discussion about global threats from zoonotic infectious diseases.>>
EMA needs Sweden’s strong scientific environment
Karin Meyer, CEO, Swedish Pharmaceutical Society about what Sweden can offer the EMA and EU.>>
Check out EIT Health and its Uppsala activities
The purpose of EIT Health is to accelerate entrepreneurship and innovation for healthy living and active ageing in Europe.>>
Fast-growing companies in Uppsala’s life science cluster
Between 2014 and 2015, the number of employees in this category increased by 11%. If we include 2013 as well, the increase is almost 20%.>>
Financial support and further action!
Our long-term goal is, as always, to contribute to growth by driving actions that complement those of the private and public sectors.>>